


(last updated  
05-17-02)

## Agenda


- [Monday, June 17th 2002](#)
- [Tuesday, June 18th 2002](#)
- [Wednesday, June 19th 2002](#)

[Home](#)[Join us](#)[Location](#)[Agenda](#)[Registration](#)[Abstract  
submission](#)

## Monday, June 17th 2002


- 8.00 a.m. Words of welcome by the local Organizing Committee  
Download the program of the day: 
- 8.15 a.m. PLENARY SESSION 1: GENETICS  
Room "Grands Lacs Baïkal-Victoria"  
CHAIRPERSONS: G. BRODEUR and M. SCHWAB  
[\(see details\)](#)
- 10.30 a.m. Break  
Coffee & Viennoiserie
- 11.00 a.m. PLENARY SESSION 2 : BIOLOGY  
Room "Grands Lacs Baïkal-Victoria"  
CHAIRPERSONS: S. COHN and H. CARON  
[\(see details\)](#)
- 12.40 p.m. Lunch time  
Room "Les Parcs"
- 2.00 p.m. PARALLEL SESSION 1: GENETICS  
Room "Grands Lacs Baïkal-Victoria"  
CHAIRPERSONS: O. DELATTRE and R. VERSTEEG  
[\(see details\)](#)
- PARALLEL SESSION 2 : BIOLOGY  
Room "Michigan"  
CHAIRPERSONS: P. KOGNER and A. NAKAGAWARA  
[\(see details\)](#)
- 5.00 p.m. to 7.00 p.m. Posters  
Room "Léman": **Biology** (30 Posters) [\(see details\)](#)  
Chair : G. Brodeur and J. Michon  
Room "Lugano-Constance": **Translational Research** (70 Posters) [\(see details\)](#)  
Chair : K. Matthey and D. Plantaz
- 7 to 9 p.m. Wellcome ceremony

## Tuesday, June 18th 2002

- 8.00 a.m. Words of welcome by the local Organizing Committee  
Download the program of the day: 
- 8.15 a.m. PLENARY SESSION 3 : BIOLOGY AND TRANSLATIONAL  
Room "Grands Lacs-Baïkal-Victoria"  
CHAIRPERSONS: J MARIS and PF. AMBROS  
[\(see details\)](#)

- 10.30 a.m. Break  
Coffee & Viennoiserie
- 11.00 a.m. PLENARY SESSION 4 : BIOLOGY AND TRANSLATIONAL  
Room "Grands Lacs-Baïkal-Victoria"  
CHAIRPERSONS: NK CHEUNG and GP TONINI  
[\(see details\)](#)
- 12.40 p.m. Lunch time  
Room "Les Parcs"
- 2.00 p.m. PARALLEL SESSION 3 : TRANSLATIONAL  
Room "Grands Lacs-Baïkal-Victoria"  
CHAIRPERSONS:  
M. HABER and D.  
VALTEAU-COUANET  
and  
T. PHILIP and A. EVANS after the  
break  
[\(see details\)](#)
- PARALLEL SESSION 4:  
CLINICAL  
Room "Michigan"  
CHAIRPERSONS: F. BERTHOLD  
and JM. ZUCKER  
and  
B DE BERNARDI and H. RUBIE  
after the break  
[\(see details\)](#)
- 5.30 p.m. to 7.15 p.m. Posters  
Room "Léman": **Genetics** (29 Posters) [\(see details\)](#)  
Chair : S. Cohn and J. Bénard  
Room "Lugano-Constance": **Clinical Research** (55 Posters) [\(see details\)](#)  
Chair : T. Sawada and R. Ladenstein
- 8 p.m. Galla dinner

Wednesday, June 19th 2002

- 8.00 a.m. Words of welcome by the local Organizing Committee  
Download the program of the day: 
- 8.15 a.m. PLENARY SESSION 5 : TRANSLATIONAL  
Room "Grands Lacs-Baïkal-Victoria"  
CHAIRPERSONS: K. MATTHAY and A. PEARSON  
[\(see details\)](#)
- 10.15 a.m. Break  
Coffee & Viennoiserie
- 11.00 a.m. PLENARY SESSION 6 : CLINICAL  
Room "Grands Lacs-Baïkal-Victoria"  
CHAIRPERSONS: O. HARTMANN and R. SEEGER  
[\(see details\)](#)
- 12.15 p.m. G. BRODEUR: CLOSING REMARKS

(last updated  
17-05-02)

## PLENARY SESSION 1: GENETICS

- 8.00 a.m. CHAIRPERSONS: G. BRODEUR and M. SCHWAB  
Room "Grands Lacs Baikal-Victoria"
- 8.15 a.m. Genetic Analysis of Tumors in a Mouse Model for Neuroblastoma  
OG-01 Hackett C, Hodgson G, Gray J, Collins C, and Weiss WA.  
University of California, San Francisco, CA, USA
- 8.35 a.m. Functional Genomics Approach to Understanding of the Genesis and Biology  
of Neuroblastoma Based on the Mass Cloning of 7,000 Genes from Three  
Clinically Different Subsets  
OG-02 Ohira M, Morohashi A, Hamano S, Machida T, Aoyama M, Fukumura M,  
Miyazaki K, Isogai E, Akazawa C, Kousaka S, Hirato J, Nakagawara A.  
Chiba Cancer Center Research Institute, Chiba, National Institute of  
Neuroscience, Tokyo, and Gunma University School of Medicine, Gunma,  
Japan
- 8.55 a.m. Positional Candidate Analysis of Neuroblastoma Suppressor Genes within  
1p36.2-p36.3  
OG-03 Gotoh T, Thompson PM, Kok M, Maris JM, White PS, Brodeur GM.  
The Children's Hospital of Philadelphia, Philadelphia, PA, USA
- 9.15 a.m. A Functional and Expression Profiling Strategy for Isolating Neuroblastoma  
(NB) Suppressor Genes on Chromosome 11  
OG-04 Maris JM, Guo C, Hii G, Wang Q, Morowitz MJ, Winter CL, Mosse Y, and  
Shusterman S.  
Children's Hospital of Philadelphia and Children's Oncology Group, USA
- OG-05 Chromosome 11q23.3-q24.1 Deletions in Neuroblastoma (NB)  
Guo C, Wang Q, Winter CL, Hii G, Morowitz MJ, Mosse Y, Shusterman S  
and Maris JM.  
Children's Hospital of Philadelphia and Children's Oncology Group, USA
- 9.45 a.m. Constitutional Mutations in the Glial Family Ligands GDNF and ARTN  
Predispose to the Development of Neuroblastoma  
OG-07 Forsyth J & McConville C.  
University of Birmingham & Birmingham Children's Hospital, UK
- 10.05 a.m. The Wiring of Neuroblastomas  
OG-08 Versteeg R, Caron H, Valentijn L, van Limpt V, Godfried M, van Sluis P,  
Lakeman A, Ropers H, Nuber U, Geerts D.  
Academic Medical Centre, Amsterdam, The Netherlands; Max Planck  
Institute, Berlin, Germany
- 10.30 a.m. Break  
Coffee & Viennoiserie

[Home](#)[Join us](#)[Location](#)[Agenda](#)[Registration](#)[Abstract  
submission](#)

(last updated  
17-05-02)

## PLENARY SESSION 2 : BIOLOGY

- 11.00 a.m. CHAIRPERSONS: S. COHN and H. CARON  
Room "Grands Lacs Baikal-Victoria"
- 11.00 a.m. Expression of BIN1, a Putative MYCN-Interacting Tumor Suppressor, is  
Reduced in Neuroblastomas with Unfavorable Biologic Features  
OB-01 Tajiri T, Liu X, Tanaka S, Suita S, Maris JM, Brodeur GM, Hogarty MD.  
The Children's Hospital of Philadelphia, PA, USA; Kyushu University, Japan
- 11.20 a.m. Downregulation of N-myc Reduces Neuroblastoma Tumorigenesis in a  
Transgenic Mouse Model  
OB-02 Haber M, Burkhart C, Marshall GM, Weiss WA, Norris MD.  
Children's Cancer Institute Australia for Medical Research, Sydney, Australia  
and University of California San Francisco, CA, USA
- 11.40 a.m. Minichromosome Maintenance Protein MCM7 is a Direct Target of the  
MYCN Transcription Factor in Neuroblastoma  
OB-03 Shohet JM, Hicks MJ, Plon SE, Burlingame SM, Stuart S, Chen SY, Brenner  
M and Nuchtern JG.  
Baylor College of Medicine; Children's Hospital, Houston, Texas; Palo Alto,  
California, USA
- 12.00 a.m. Expression Profiling of TrkB Transfected Neuroblastoma Cells Reveals  
Cadherin 11 and MCSP as Potential New Target Genes of TrkB/BDNF  
Signaling  
OB-04 Schulte JH, Schramm A, Klein-Hitpass L, Brodeur GM, Havers W, Eggert A.  
University Children's Hospital of Essen, Germany and The Children's Hospital  
of Philadelphia, PA, USA
- 12.20 p.m. Identification and Characterisation of Apoptosis-Sensitizing Genes in  
Neuroblastoma  
OB-05 Wittke I, Wiedemeyer R, Savelyeva L and Schwab M.  
Deutsches Krebsforschungszentrum Heidelberg, Germany
- 12.40 p.m. Lunch  
Room "Les Parcs"

[Home](#)[Join us](#)[Location](#)[Agenda](#)[Registration](#)[Abstract  
submission](#)

(last updated  
05-07-02)

## PARALLEL SESSION 1: GENETICS

- 2.00 p.m. CHAIRPERSONS: O. DELATTRE and R. VERSTEEG  
Room "Grands Lacs Baikal-Victoria"
- 2.00 p.m. Construction and Clinical Use of the Neuroblastoma cDNA Microarray for Predicting the Prognosis  
OG-08 Ohira M, Morohashi A, Hamano S, Machida T, Aoyama M, Fukumura M, Miyazaki K, Isogai E, Akazawa C, Kousaka S, Hirato J, Nakagawara A. Chiba Cancer Center Research Institute, Chiba., National Institute of Neuroscience, Tokyo, Gunma University. School of Medicine, Gunma, Japan
- 2.15 p.m. Gene Expression Profiling of Progressing Versus Regressing Neuroblastomas with cDNA Microarrays  
OG-09 Westermann F, Wei J, Wiedemeyer R, Whiteford C, Fischer M, Ernestus K, Berthold F, Schwab M and Khan J. Advanced Technology Center, National Cancer Institute, Gaithersburg, USA. German Cancer Research Center, Heidelberg, Germany
- 2.30 p.m. Micro-Array Analysis of Neuroblastoma Tumor Samples: High Expression of Immunity-Related Genes in Low Risk Tumors  
OG-10 Alaminos M, Cheung NKV, Mora J, Qin J, Smith A, Gerald WL. Memorial Sloan-Kettering Cancer Center, New York, NY, USA
- 2. 45 p.m. Subtractive Expression Profiling between Two Genetic Subgroups of Neuroblastoma  
OG-11 Vandesompele J, Pattyn F, De Preter K, Van Roy N, Swerts K, Hoebeeck J, Laureys G, De Paepe A, Philippe J, Speleman F. Center for Medical Genetics, Ghent University Hospital, Belgium
- 3.00 p.m. Forward Genetic Screens for Mutations Affecting the Development of the Peripheral Sympathetic Nervous System in the Zebrafish Model  
OG-12 George R, Rauh-Adelmann C, Grant A, Kanki J, Rhodes J, Palomero T, Look AT. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
- 3.15 p.m. Deletion Mapping and Mutation Analysis of 11q23 in non-MYCN Amplified, Intermediate Type of Neuroblastoma  
OG-13 Arai Y, Kubo T, Gamou T, Hosoda F, Sakiyama T, Toyoda A, Hattori M, Sakaki Y, Ohira M, Nakagawara A, Ohki M. National Cancer Center Research Institute., Tokyo; RIKEN Genomic Sciences Center, Yokohama; Chiba Cancer Center Research Institute, Chiba, Japan
- 3.30 p.m. Break  
Coffee & vienoeseries
- 4.00 p.m. A Constitutional Translocation t(1;17) in a Neuroblastoma Patient Disrupts a Novel Candidate Tumor Suppressor Gene  
OG-14 Vandepoele K, Staes K, Van Roy N, Berx G, Speleman F, Van Roy F. Ghent University Hospital, Ghent, Belgium
- 4.15 p.m. No Evidence for Imprinting at Chromosome Subband 1p36.3 in Neuroblastoma  
OG-15 Winter CL, Maris JM, Liu X, Guo C, Look AT, White PS, Brodeur GM and Hogarty MD. Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA; Dana Farber Cancer Institute, Boston, MA; Children's Oncology Group, USA
- 4.30 p.m. Analysis of Genes Down Regulated by N-myc in Neuroblastoma

[Home](#)[Join us](#)[Location](#)[Agenda](#)[Registration](#)[Abstract submission](#)

OG-16

Valentijn LJ, van Asperen R, Schwab M, and Versteeg R.  
Academic Medical Center, Amsterdam, the Netherlands, German Cancer  
Center, Heidelberg, Germany

(last updated  
05-07-02)

## PARALLEL SESSION 2 : BIOLOGY

- 2.00 p.m. CHAIRPERSONS: P. KOGNER and A. NAKAGAWARA  
Room "Michigan"
- 2.00 p.m. Loss of One HUD Allele on Chromosome 1p is Linked to Amplification of  
N-myc in Human Neuroblastoma Cells  
OB-06 Ross RA, Lazarova DL, Barton KB, Biedler JL, Spengler BA.  
Fordham University, Bronx, NY USA
- 2.15 p.m. Np73, Mapped to 1p36 2-3, Induces Its Own Splicing Variant DeltaNp73,  
Which Negatively Regulate p53 and p73 Function by Promoting Cell Survival  
in SH-SY5Y Neuroblastoma Cells Treated with Cisplatin: Identification of  
p73-Specific Target Element within the deltaNp73 Promoter  
OB-07 Nakagawa T, Takahashi M, Ozaki T, Watanabe K, Hayashi S, Hosoda M,  
Todo S, and Nakagawara A.  
Chiba Cancer Center Research Institute, Chiba, Hokkaido University School  
Medicine, Sapporo, Japan
- 2.30 p.m. Nuclear p53 Expression is Associated with High-Risk, Undifferentiated  
Neuroblastoma, p21<sup>WAF1</sup> Expression, MYCN Amplification and MYCN  
Expression  
OB-08 Tweddle DA, Malcolm AJ, Wood KM, Reid MM, Cole M, Variend S,  
Cullinane CC, Pearson ADJ and Lunec J.  
University of Newcastle, Sheffield Children's Hospital and St James's  
University Hospital, Leeds, U.K.
- 2. 45 p.m. Distinct Mechanisms of Cell Cycle Arrest Control the Decision between  
Differentiation and Senescence in Neuroblastoma  
OB-09 Lasorella A and Iavarone A.  
Cancelled Albert Einstein College of Medicine, New York, NY, USA
- 3.00 p.m. Activin A Expression Impairs the Malignant Potential of Neuroblastoma Cells  
in Vitro and in Vivo  
OB-10 Schweigerer L, Breit S, Fotsis T, Schramm A.  
University Children's Hospital of Essen, Germany
- 3.15 p.m. Differences in Neurotrophin-Mediated Signal Transduction and Early Gene  
Induction in Human Neuroblastoma (NB) Cells Expressing TrkA or TrkB  
OB-11 Minturn JE, Hishiki T, Ho R, Ikegaki N, Brodeur GM.  
Children's Hospital of Philadelphia, PA USA
- 3.30 p.m. Break  
Coffee & vienoeseries
- 4.00 p.m. Schwann Cells Produce a Spectrum of Factors that Induce Endothelial Cell  
Apoptosis and Inhibit Angiogenesis  
OB-12 Chlenski A, Crawford SE, Salwen HR, and Cohn SL  
Northwestern University, Chicago, IL, USA
- 4.15 p.m. Nestin is a Potential Mediator of N-myc Activity in Human Neuroblastoma  
OB-13 Thomas S, Spengler BA, Messam CA, Biedler JL, Ross RA.  
Fordham University, Bronx, NY, and NINDS, NIH, Bethesda, MD, USA
- 4.30 p.m. Rapamycin Inhibits Growth of Human Neuroblastoma Cells without  
Suppression of N-Myc Induction  
OB-14 Misawa A, Hosoi H, Tsuchiya K, and Sugimoto T.  
Department of Pediatrics, Kyoto Prefectural University of Medicine, Japan

[Home](#)[Join us](#)[Location](#)[Agenda](#)[Registration](#)[Abstract  
submission](#)

## POSTER SESSION 1 : BIOLOGY

CHAIRPERSONS: R. CASTELBERRY and J. MICHON  
Room "Leman"

- PB-01 Murine neuroblastoma models featuring regulable MYCN expression and markers for early tumor detection  
Chesler L, Weiss WA.  
UCSF, San Francisco, CA, USA
- PB-02 Expression Analysis on Normal Neuroblasts Isolated from Fetal Adrenals Using Laser Capture Micro-Dissection  
De Preter K, Vandesompele J, Heimann P, Kockx M, Van Roy N, and Speleman F.  
Ghent University Hospital, Ghent, University Hospital Erasme, Brussels, and Middelheim Hospital, Antwerp, Belgium
- PB-03 Distinct Cytogenetic Pathways of Advanced Stage Neuroblastoma Detected by Spectral Karyotyping  
Stark B, Jeison M, Bar-Am I, Galser-Gabay L, Mardoukh J, Goshen Y, Stein J, Zaizov R, Yaniv I. Schneider Children's Medical Center of Israel, Petah-Tikva, Sackler Faculty of Medicine, Tel Aviv University and Applied Spectral Imaging, Migdal Haemek, Israel
- PB-04 Ectopic Expression of MCYN Enhances the Proliferation Effect of Neurotrophins in SH-SY5Y Neuroblastoma (NB) Cells  
Hishiki T, Ho R, Minturn JE, Ikegaki N, Brodeur GM.  
The Children's Hospital of Philadelphia, Philadelphia, USA
- PB-05 Does DDX1 co-amplification with MYCN have a role in neuroblastoma?  
Elsden JL, Kenyon RM, George RE, Godbout R, Pearson ADJ and Lunec J.  
University of Newcastle upon Tyne, Newcastle upon Tyne, UK
- PB-06 Deregulated MYCN Induces Apoptosis in Primary Human Cells of Neuroectodermal Origin  
Liu X, Tajiri T, Dam V, Hogarty MD.  
The Children's Hospital of Philadelphia, USA
- PB-07 ID2 is a MYCN Target Gene, but Expression is not Correlated with MYCN Gene Amplification in Human Neuroblastomas  
Wang Q, Guo C, Hii G, Shusterman S, Mosse Y, Zhao H, Cnaan A, Hogarty MD and Maris JM. Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA and Children's Oncology Group, USA
- PB-08 Id Proteins in Human Neuroblastoma Cells: Expression and Interaction with Neuronal bHLH Proteins.  
Persson P, Jögi A, Grynfeld A, Pählman S, and Axelson H.  
Lund University, University Hospital MAS, Malmö, Sweden
- PB-09 The Role of the Chromosome 17q Genes nm23-H1 and nm23-H2 in Neuroblastoma  
Godfried MB, van Sluis P, Versteeg R and Caron HN.  
Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
- PB-10 E-box Mediated Regulation of the MRP Promoter in Human Neuroblastoma  
Manohar CF, Bray JA, Salwen H, Norris MD, Haber M, and Cohn SL.  
Departments of Pediatrics and The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Chicago, IL, USA and the Children's Cancer Institute Australia for Medical Research, Sydney, Australia

[Home](#)[Join us](#)[Location](#)[Agenda](#)[Registration](#)[Abstract  
submission](#)



- PB-11 Attenuated G1 Arrest in Neuroblastoma is Mediated by Differential Localization of Cdk2 and p21<sup>Waf-1/Cip-1</sup>  
McKenzie PP, Danks MK, Harris LC.  
St. Jude Children's Research Hospital, Memphis, TN, USA
  
- PB-12 The p53 Gene is Frequently Mutated in Cell Lines but not in Fresh Tumors of Neuroblastoma within All Coding Sequences  
Tanaka K, Takita J, Taketani T, Hanada R, Yamamoto K, Hashizume K, and Hayashi Y.  
University of Tokyo Hospital, Tokyo, and Saitama Children's Medical Center, Saitama, Japan
  
- PB-13 The Transcription Factor HAND2 Regulates the Development in Neuroblastoma Cells  
Morikawa Y, Hwang S, Chun S, Venuti J and Cserjesi P.  
Columbia University, New York, NY, and Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA
  
- PB-14 Delta-Notch Signaling in Neuroblastoma Differentiation  
Van Limpt V, Chan A, Caron H, van Sluis P and Versteeg R.  
Academic Medical Center, Amsterdam, The Netherlands
  
- PB-15 The NOTCH-1 Signalling Cascade in Differentiating Neuroblastoma Cells  
Stockhausen M, Axelson H.  
Unit for Molecular Medicine, MAS, Lund University, Malmö, Sweden
  
- PB-16 Induction of Galanin Receptor Subtype 3 Expression Leads to Morphological Changes in the Neuroblastoma Cell Line SH-SY5Y  
Berger A, Sperl W, Kofler B.  
Children's Hospital, Salzburg, Austria
  
- PB-17 Galanin and Galanin Receptor Expression in Neuroblastic Tumours : Correlation with their Differentiation Status  
Perel Y, Amrein L, Dobremez E, Rivel J, Daniel JY, Landry M.  
University of Bordeaux 2, Children's Hospital, University Hospital, Bordeaux, France
  
- PB-18 Expression of Pax5 in N-type Neuroblastoma Cell Lines  
Baumann FB, Himmelmann A.  
University Hospital, Zurich, Switzerland
  
- PB-19 Neuroblastoma and the PML Nuclear Body (NuB)  
Bloch DB, Nakajima A, Yu J, Nakajima H, Diller LR, Bloch KD.  
Harvard Medical School, Boston, MA, USA
  
- PB-20 Unveiling the Apolipoprotein J Signalling Network: Implications for Neuroblastoma Cell Survival  
Pagnan G, Santilli G, and Sala A.  
The Institute of Child Health, London UK; Section of Medical Oncology, Chieti, Italy
  
- PB-21 BTG2<sup>TIS21/PC3</sup> Induces Neuronal Differentiation and Prevents Apoptosis of Terminally Differentiated PC12 Cells  
Schell M, Combaret V, El Ghissassi F, Falette N, Bergeron C, et Puisieux A.  
Centre Léon Bérard, Lyon, France
  
- PB-22 Signal Transduction Pathways Through TRK-A Receptors in Neuroblastoma Cell Lines and Primary Tumor Tissues  
Sugimoto T, Kuroda H, Moritake H, Horii Y, Tajiri T, Suita S, Fukushige T, Takamatsu H.  
Kyoto Prefectural University of Medicine; Miyazaki Medical College; Kyushu University; Kagoshima University, Japan
  
- PB-23 The p73 Target Genes in Human Malignant Neuroblasts are Related to Neuronal Development and Sympathetic Differentiation

Goldschneider D, Blanc E, Raguéñez G, Legrand A, Taisant O, Le Roux G, Bénard J, Haddada H, Douc-Rasy S.  
Institut Gustave Roussy, 94805 Villejuif, France

- PB-24 Ataxin2 Sensitizes Neuroblastoma Cells for Apoptosis  
Wiedemeyer R, Westermann F, Wittke I and Schwab M.  
German Cancer Research Center
  
- PB-25 Multiple Mechanisms Prevent MHC-Class II Expression in NB  
Croce M, De Ambrosis A, Corrias MV, Accolla RS, Occhino M, Mazza S, Meazza R, Pistoia V, and Ferrini S.  
Istituto Nazionale per la Ricerca sul Cancro, Istituto G. Gaslini, Genoa;  
Università della Insubria Varese; Italy
  
- PB-26 Intercellular Adhesion Molecule-2 (ICAM-2) Expression in Neuroblastoma  
Danks MK, Davidoff AM, Potter PM.  
St. Jude Children's Research Hospital, Memphis, TN, USA
  
- PB-27 I-Type Stem Cells are Components of Human Neuroblastoma Tumors as well as Cell Lines  
Spengler BA, Walton JD, Biedler JL, Mora J, Gerald WL, Cheung N-KV, Ross RA.  
Fordham University, Bronx NY and Memorial Sloan-Kettering Cancer Center, New York, NY, USA
  
- PB-28 A Possible New Role for Filamins in Natural Human IgM-mediated Apoptosis in Neuroblastoma  
Bachmann AS, Heiligtag S, Howard JP, David K, and Vogel CW.  
Cancer Research Center of Hawaii, University of Hawaii, Honolulu, Hawaii, USA
  
- PB-29 Hypoxic Treatment of Human Neuroblastoma Cells Alters the Gene Expression toward a More Immature Phenotype  
Jögi A, Øra I, Nilsson H, Poellinger L, Axelson H and Pählman S.  
Lund University, CMB, Medical Nobel Institute, Karolinska Institute, Sweden
  
- PB-30 Phenotypic changes in human neuroblastoma cells induced by hypoxia and hypoglycemia  
Nilsson H, Jögi A, Pählman S.  
Lund University, University Hospital MAS, Malmö, Sweden

## POSTER SESSION 2 : TRANSLATIONAL

CHAIRPERSONS: K. MATTHAY and D. PLANTAZ  
Room "Lugano-Constance"

- PT-01 Neurotrophin Receptors TrkA and TrkB Both Enhance Survival of Irradiated Neuroblastoma Cells, Probably Using Different Mechanisms  
Hilder G, Schramm A, Díaz-Carballo D, Sieverts H, Brodeur GM, Havers W, Eggert A.  
University Children's Hospital of Essen, Germany and The Children's Hospital of Philadelphia, Philadelphia PA, USA
- PT-02 17q Gain - a Genetic Marker Independent from Diploidy?  
Stock C, Luegmayr A, Vallant E, Ladenstein R, Ambros PF, Ambros IM.  
CCRI, St. Anna Kinderspital, Vienna, Austria
- PT-03 Expression of P27<sup>KIP1</sup> is Prognostic and Independent of MYCN Amplification in Human Neuroblastoma.  
Bergmann E, Wanzel M, Weber A, Shin IH, Berwanger B, Eilers M and Christiansen H.  
University Children's Hospital, and Institute of Molecular Biology and Tumour Research, Marburg, Germany
- PT-04 Automatic Quantification of MYCN Amplification in Clinical Samples  
Narath R, Ambros PF.  
CCRI, St. Anna Kinderspital, Vienna, Austria
- PT-05 Impact of Apo3 and Apo3-Ligand Expression on Patient Survival in Primary Neuroblastomas  
Eggert A, Grotzer MA, Zuzak TJ, Ikegaki N, Zhao H, Brodeur GM.  
University Children's Hospital of Essen, Germany, University Children's Hospital of Zurich, Switzerland and The Children's Hospital of Philadelphia, USA
- PT-06 Gene Expression Profiling in Neuroblastoma: Biological Insights and Clinicopathologic Correlation  
Hill DA, Riedley SE, Yeoh AEJ, Shurtleff SA, Patel DH, Williams WK, Pappo AS, Downing JR.  
St. Jude Children's Research Hospital, Memphis, TN, USA
- PT-07 Elevated Level of Serum Midkine Is Significantly Correlated with Advanced Stages, Older Age, MYCN Amplification, Decreased Expression of TrkA and Diploid Karyotype in Human Neuroblastomas  
Kadamatsu K, Ikematsu S, Muramatsu H, Takei Y, Sakuma S, Nakamura Y, Muramatsu T, and Nakagawara A.  
Nagoya University School of Medicine, Nagoya; Pharmaceutical Development Department, Meiji Milk Products Co., Ltd., Odawara ; Chiba Cancer Center Research Institute, Chiba; Japan
- PT-08 Prospective Validation of Real-Time Quantitative PCR for Detection of MYCN Amplification in Primary Neuroblastoma Specimens  
Hii G, Shusterman S, Winter C, Guo C, Wang Q, Mosse Y, Morowitz MJ, Moreau L, Look AT and Maris JM.  
Children's Hospital of Philadelphia and University of Pennsylvania, Dana Farber Cancer Institute and Children's Oncology Group, USA
- PT-09 Novel Human Nbla0761/hRIM1, a Gene of the Synaptic Rab3-Interacting Molecule, is Expressed Significantly at High Levels in Neuroblastomas with Favorable Outcome

[Home](#)[Join us](#)[Location](#)[Agenda](#)[Registration](#)[Abstract  
submission](#)

Aoyama M, Asai K, Ohira M, Shishikura T, Kawamoto T, Inuzuka H, Hirato J and Nakagawara A.

Chiba Cancer Center Research Institute, Chiba; Nagoya City University Medical School, Nagoya; Gunma University School of Medicine, Maebashi; Japan

- PT-10      Role of the Candidate Tumor Suppressor ING1 in Neuroblastoma and Identification of the ING1 Target Genes Using Genetic Suppressor Element Procedure and cDNA Microarray  
Takahashi M, Ozaki T, Nakagawa T, Watanabe K, Hayashi S, Hosoda M, Ohira M, Seki N, Mizuguchi H, Hayakawa T, Todo S, and Nakagawara A.  
Chiba Cancer Center Research Institute, and Helix Research Institute, Chiba; Hokkaido University School of Medicine, Sapporo; National Institute of Health Science, Tokyo; Japan
  
- PT-11      The Primary Culture of 195 Neuroblastomas: Functional Responsiveness to NGF, but not Retinoic Acid or GDNF family factors, is Significantly Associated with Favorable Outcome  
Nakanishi H, Ueda K, Sugimitsu N, Nakamura Y, Isogai E, Takada N, Kuno T, Takayasu H, Hashizume K, and Nakagawara A.  
Chiba Cancer Center Research Institute, Chiba; University of Tokyo, Tokyo; Kurume University School of Medicine, Kurume; Japan
  
- PT-12      MYCN Overexpression Drives Chemoresistance in Human Metastatic Neuroblasts  
Blanc E, Goldschneider D, Douc-Rasy S, Le Roux G, Ferrandis E, Barrois M, Bénard J, Raguénez G. Institut Gustave Roussy, Villejuif, France
  
- PT-13      Genetics groups of Neuroblastoma Patients Defined by Molecular and Conventional Cytogenetics  
Glaser-Gabay L, Jeison M, Mardouk J, Luria D, Stein J, Goshen Y, Zaizov R, Yaniv I, Stark B.  
Schneider Children's Medical Center of Israel, Sackler School of Medicine, Tel-Aviv University, Israel.
  
- PT-14      Differential Gene Expression Profiles of Favorable and Unfavorable Neuroblastomas  
Ishii M, Takita J, Shuichi T, Hanada R, Yamamoto K, Tanaka Y, Hayashi Y and Aburatani H.  
University of Tokyo, Tokyo; Saitama Children's Medical Center, Saitama; Kanagawa Children's Medical Center, Kanagawa; Japan
  
- PT-15      Comparative Assessment of MYCN Gene Dosage and Expression  
Tanaka S, Tajiri T, Shono K, Noguchi S, Ihara K, Hara T, Suita S..  
Kyushu University, Japan
  
- PT-16      High Specificity for Prognostic Prediction of Neuroblastomas : A Combination of N-MYC Amplification, the Shimada System and HA-RAS/TRK A Expression Increases Predictive Efficiency  
Tanaka T, Iehara T, Hosoi S, Sugimoto T, Suita S, Tsuchida Y, Sawada T.  
National Hospital Kure Medical Center, Hiroshima; Kyoto Prefectural University of Medicine, Kyoto; The Japanese Infantile Neuroblastoma Cooperative Study, The Japanese Advanced Neuroblastoma Cooperative Study, Japan
  
- PT-17      MYCN Gene Gain in Primary Neuroblastoma without Amplification: Mechanisms and Influence on Tumor Evolution  
Valent A, Bénard J, Danglot G, Barrois M, Terrier-Lacombe MJ, Valteau-Couanet D, Hartmann O, Spengler B, Lenoir G and Bernheim A.  
Institut Gustave Roussy, Villejuif, France, and Fordham University, Bronx, NY, USA
  
- PT-18      Elimination of Amplified MYCN Sequences from Primary Neuroblastoma Tumor Cells through the Formation of Micronuclei

Valent A, Valteau-Couanet D, Terrier-Lacombe MJ, Spengler B, Barrois M, Bénard J, Lenoir G and Bernheim A.  
Institut Gustave Roussy, Villejuif, France and Fordham University, Bronx, NY, USA

- PT-19 Additional 17q in Neuroblastoma Cell Lines: Analysis of the Smallest Overrepresented Region by FISH  
Valent A, Guillaud-Bataille M, Meddeb M, Bénard J, Fauvet D, Perot C, Léon B, Bernheim A and Danglot G.  
Institut Gustave Roussy, Villejuif, France
  
- PT-20 Sensitive Detection of Chromosome 1p Deletion in Neuroblastoma by Three Color Interphase Fluorescence in Situ Hybridization  
Van Roy N, Vandesompele J, De Smet E, Laureys G, De Paepe A, Speleman F.  
Ghent University Hospital, Ghent, Belgium
  
- PT-21 Hypermethylation-Mediated Regulation of CD44 Expression in Human Neuroblastoma  
Yan P, Balmas Boulroud K, Nenadov Beck M and Gross N.  
CHU Vaudois, Lausanne, Switzerland
  
- PT-22 In Vitro and in Vivo NB Expression of Co-Stimulatory Molecules  
Corrias MV, Airoidi I, Occhino M, Lualdi S, and Pistoia V.  
Istituto G. Gaslini, Genoa, Italy
  
- PT-23 Activation of the N-Myc-Id2-Rb Pathway in Neuroblastoma  
Presentation cancelled  
Lasorella A and Iavarone A.  
Albert Einstein College of Medicine, New York, USA
  
- PT-24 The Tyrosine Kinase Inhibitor CEP2563 (KT8391) Sensitizes TRKB Expressing Neuroblastoma (NBL) Tumors to Chemotherapy  
Evans AE, Moriyama H, Ho R, Ruggeri B, Brodeur GM.  
The Children's Hospital of Philadelphia, Philadelphia, and Cephalon, Inc., West Chester, PA, USA
  
- PT-25 Unambiguous Detection of Tumor Cells in the Bone Marrow from Neuroblastoma Patients - Fantasy or Reality?  
Ambros PF, Mehes G, Luegmayr A, Ambros IM, Vallant E, Gadner H, Ladenstein R.  
CCRI, St. Anna Kinderspital, A-1090 Vienna, Austria
  
- PT-26 Proton NMR Spectroscopy for Monitoring of Neuroblastoma Viability in Vivo and in Vitro  
Lindskog M, Spenger C, Ponthan F, Sandstedt B, Jarvet J, Graslund A, Schweinhardt P, Helms G, Kogner P.  
MR Center, Karolinska Hospital, Karolinska Institutet and Stockholm University, Stockholm, Sweden
  
- PT-27 Three Methods of Stem Cell Selection Provide Tumor Cell Purging from Stem Cell Products  
Grupp SA, Ash S, Fang J, Pierson G, Gribben J, and Diller L.  
Children's Hospital of Philadelphia and Dana-Farber Cancer Institute, Boston, USA
  
- PT-28 Loss of Caspase-8 Expression in Neuroblastoma Cells is not Associated with Resistance to Cell Death Induced by Cytotoxic Drugs or Irradiation  
Radü J, Pöttgen C, Sieverts H, Havers W, Eggert A.  
University Children's Hospital of Essen, Germany
  
- PT-29 Drug-Induced Apoptotic Pathways in Caspase 8 Silenced Neuroblastoma Cells

Gross N, Hopkins Donaldson S, Yan P, Bodmer JL, Muhlethaler A, Balmas Bourlout K, Joseph JM, Nenadov Beck M.  
CHUV, Institute of Biochemistry, Lausanne University, Laboratory of Oncology, University Hospital, Zürich, Switzerland

- PT-30      Activation of TRKB Mediates Cytoprotection against Chemotherapy in Neuroblastoma  
Jaboin J, Van de Geijn G, Kim CJ, Kaplan D and Thiele CJ.  
National Institute of Health, Bethesda, MD, USA and Montreal Neurological Institute, Montreal, Canada
  
- PT-31      Interferon- $\gamma$  Elevates Caspase-8 Expression and Sensitizes Human Neuroblastoma Cells to TRAIL-Mediated Apoptosis  
Johnsen JI, Mikkelsen I, Karnhed N, Halvorsen H, Pettersen I, Alstad H, Kogner P, Sveinbjørnsson B, Flægstad T.  
Faculty of Medicine, University of Tromsø, Norway and Karolinska Institutet, Stockholm, Sweden
  
- PT-32      Arsenic Trioxide-Induced Cell Death Mechanisms in Human Neuroblastoma Cells  
Karlsson J, Øra I, Pörn-Ares I and Pählman S.  
Lund University, Malmö, Sweden
  
- PT-33      Inducible MYCN Enhances DNA Synthesis, Spontaneous Apoptosis, and Drug-Sensitivity in a MYCN non-Expressing Neuroblastoma Cell Line  
Goto H, Alfaro PA, Weiss WA, Reynolds CP.  
Childrens Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, CA; University of California, San Francisco, CA, USA
  
- PT-34      Pyrazoloacridine Induces both Apoptosis and Necrosis, and Is Active in Multi-Drug-Resistant Neuroblastoma Cell Lines with non-Functional p53  
Keshelava N, Reynolds CP.  
Childrens Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, CA, USA
  
- PT-35      Assessment of Spontaneous and Chemotherapy Induced Apoptosis in Short Term Cultures of Primary Neuroblastoma (NB) Tissue  
Sieverts H, Pietrzak A, Elsesser S, Peretyatko N and Zachariou Z.  
University Children's Hospital Heidelberg, and University of Heidelberg, Germany
  
- PT-36      Cisplatin Sensitivity, DNA Adduct Formation and p53 Functional Status in Neuroblastoma Cell Lines  
Tweddle DA, Tilby MJ, Malcolm AJ, Pearson ADJ and Lunec J.  
University of Newcastle, U.K
  
- PT-37      Characterization of a Neuroblastoma Xenograft whose Resistance to Irinotecan was Acquired in Vivo in a Therapeutic Setting  
Calvet L, Santos A, Terrier-Lacombe MJ, Merlin JL, Bénard J, Lavelle F, Aubert G, Morizet J, Schellens JHM, Vassal G.  
Institut Gustave-Roussy, Villejuif ; C.A. Vautrin, Nancy ; Aventis, Vitry/Seine ; France. Netherland Cancer Institute, Amsterdam, Netherlands
  
- PT-38      12-Lipoxygenase Mediates Induction of Reactive Oxygen Species in Fenretinide-Induced Apoptosis of Neuroblastoma  
Lovat P, Ranalli M, Corrazzari M, Raffaghello L, Pearson A, Ponzoni M, Piacentini M, Melino G and Redfern C..  
University of Newcastle upon Tyne, UK, University Tor Vergata, Rome, G.Gaslini Children's Hospital, Genoa, Italy
  
- PT-39      Regulation of Retinoic Acid Induced Differentiation of Neuroblastoma by SRC Kinase

Dey N, De PK, Robertson KA and Durden DL.  
Herman B Wells Center for Pediatric Research, Indiana University School of  
Medicine, Indianapolis, IN, USA

- PT-40 RAR $\gamma$  Protects Neuroblastoma Cells from Fenretinide - Induced Apoptosis but Increases Cell Death with Natural Retinoids  
Goranov BB, Campbell-Hewson Q, Rana B, Ranalli M, Lovat P, Redfern C.  
University of Newcastle upon Tyne, UK and University of Tor Vergata,  
Rome, Italy
- PT-41 Growth Inhibitory Retinoid to the Retinoic Acid? Effects Follow Recruitment of Retinoid X Receptor Receptor  $\beta$  Promoter  
Cheung B, Yan J, Smith S, Kavallaris M, Norris M, Haber M and Marshall G.  
Children's Cancer Institute Australia for Medical Research, Sydney Australia
- PT-42 Ro 13-6307, a Novel Retinoid for Neuroblastoma Differentiation Therapy?  
Ponthan F, Klevenvall L, Johnsen JI, Kogner P.  
Childhood Cancer Research Unit, Karolinska Institutet, Stockholm, Sweden
- PT-43 Inhibition of Neuroblastoma-Induced Angiogenesis by Fenretinide  
Ribatti D, Alessandri G, Raffaghello L, Cosimo E, Montaldo PG, Vacca A, Ponzoni M.  
University of Bari; Institute of Microbiology, University of Brescia; G.  
Gaslini Children's Hospital, Genoa, Italy
- PT-44 Potentiation of RA-Induced Growth Arrest or Apoptosis of Neuroblastoma by Trichostatin A at IC<sub>50</sub> or Lower Concentrations  
Rikiishi T, Imaizumi M, Stauffer J, Inuma K, Thiele CJ and Hayashi Y .  
Department of Pediatric Hematology and Oncology, Department of  
Pediatrics, Tohoku University School of Medicine, Sendai, Japan; National  
Institute of Health, Bethesda, MD, USA
- PT-45 A Clusianon-Derivative is a Potent Novel Compound with Cytotoxic Activity in Neuroblastoma Cells  
Díaz-Carballo D, Lindtner B, Hilger R, Seeber S, Drothler A, Schramm A, Havers W, Eggert A.  
University Children's Hospital of Essen, Germany
- PT-46 Betulinic Acid and its Derivatives: Novel Strategies for the Treatment of Neuroblastoma  
Fulda S, Debatin KM.  
University Children's Hospital, Ulm, Germany
- PT-47 Neuroblastoma Directed Therapy by a Rational Prodrug Design of Etoposide as a Substrate for Tyrosine Hydroxylase  
Jiang J, Shabat D, Huebener N, Schroeder U, Wrasidlo W, Wenkel J, Lange B, Gaedicke G, Lode HN.  
Charité Childrens Hospital, Berlin, Germany and School of Chemistry,  
Tel-Aviv University, Tel-Aviv, Israel
- PT-48 The Biphosphonate Zoledronate Reduces Experimental Neuroblastoma Growth by Interference with Tumor Angiogenesis  
Bäckman U, Green J and Christofferson R.  
Novartis Pharma A-G, Basel, Switzerland, and Children's Hospital, Uppsala  
University, Sweden
- PT-49 A New Biological Approach to Study the Synergism of Hyperthermia and Cisplatin Against LAN1 Neuroblastoma Cells: Differential Gene Expression Analyzed by Oligonucleotide Arrays  
Schramm A, Schulte JH, Klein-Hitpass L, Kremens B, Havers W, Eggert A
- PT-50 Growth Inhibition of Neuroblastoma Cell Lines by the Tyrosine Kinase Inhibitor STI571

Combaret V, Frappaz D, Capdeville R, Ranchere D, Iacono I, Bergeron C and Puisieux A.  
Centre Léon Bérard, Lyon, France and Novartis Oncology Basel, Switzerland

- PT-51 A Novel Syngeneic Murine Model for Thoracic Neuroblastoma  
Corrias MV, Bocca P, Cilli M, Pistoia V and Gambini C.  
Istituto G. Gaslini; Istituto Nazionale per la Ricerca sul Cancro; Genoa, Italy
- PT-52 A New Generation of non-Toxic Tumor Targeted Anticancer Agents  
Pecere T, Bet A, Salata C, De Bernardi B, Carli M, Palù G.  
Medical School, University of Padova, Children Hospital G. Gaslini, Genova, Italy
- PT-53 Selective Inhibition of the Metastatic Growth of Neuroblastoma Cells by Immunoliposomes Containing Doxorubicin  
Pastorino F, Brignole C, Marimpietri D, Moase EH, Allen TM and Ponzoni M.  
G. Gaslini Children's Hospital, Genoa, Italy and University of Alberta, Edmonton, Canada
- PT-54 A Xenograft Model of Human Neuroblastoma Bone Metastases in Immunodeficient (SCID) Mice  
Goto S, Shimada H, Sun BC, Maurer BJ, Sohara Y, Scadeng M, Pollack H, Nelson MD, DeClerk YA, Reynolds CP.  
Childrens Hospital Los Angeles and University of Southern California, Los Angeles, CA, USA
- PT-55 Antagonism of Buthionine Sulfoximine Cytotoxicity for Human Neuroblastoma Cell Lines by Hypoxia is Reversed by the Bioreductive Agent Tirapazamine  
Yang B, Keshelava N, Anderson CP, Reynolds CP.  
Children's Hospital Los Angeles and The University of Southern California, Los Angeles, CA, USA
- PT-56 Up-regulation of Erythropoietin in Neuroblastoma by Hypoxia Is Restricted to Cells with Neuronal Phenotype  
Rössler J, Stolze I, Frede S, Schweigerer L, Havers W, Fandrey J.  
Universitätsklinikum Essen, Germany
- PT-57 TRAIL-Induced Apoptosis is Inhibited by Bcl-2 in Type II Neuroblastoma Cells  
Fulda S, Debatin KM.  
University Children's Hospital, Ulm, Germany
- PT-58 Smac Peptides or Smac Gene Transfer: Novel Strategies to Overcome Resistance of Neuroblastoma Cells against Anticancer Drug- or TRAIL-Induced Apoptosis  
Fulda S, Debatin KM.  
University Children's Hospital, Ulm, Germany
- PT-59 Dimeric Anti-GD2 Small Immunoproteins as Potential Therapeutic Tools for Neuroblastoma  
Occhino M, Corrias MV, Burrone O, Pistoia V, and Bestagno M.  
ICGEB, Trieste; Gaslini Children's Hospital, Genova; Italy
- PT-60 Vaccination with Minigenes Encoding for Novel "Self" Antigens Are Effective in DNA-Vaccination against Neuroblastoma  
Huebener N, Schroeder U, Lemmel C, Rammensee HG, Wrasidlo W, Wenkel J, Lange B, Jiang J, Gaedicke G, Lode HN.  
Charité Childrens Hospital, Berlin; University of Tübingen, Tübingen; Germany
- PT-61 Study of IL-15 and/or IL-12 Gene Transfer in Murine NB



Croce M, Corrias MV, De Ambrosis A, Orengo AM, Comes A, Cilli M, Gambini C, Pistoia V, and Ferrini S.  
Istituto per la Ricerca sul Cancro; Istituto G. Gaslini; Genoa, Italy

- PT-62      STK15 Can Function as a Surrogate for MYCN in immunotherapy of MYCN-Amplified Neuroblastoma  
Nuchtern J and Sarkar A.  
Baylor College of Medicine and Texas Children's Cancer Center, Houston, TX, USA
  
- PT-63      Antitumor Activity of Anti-GD2 mAb in a Metastatic Neuroblastoma Model in Vivo  
Raffaghello L, Pagnan G, Pastorino F, Brignole C, Cosimo E, Marimpietri D, Montaldo PG and Ponzoni M.  
G. Gaslini Children's Hospital, Genoa, Italy
  
- PT-64      Targeted Delivery and Anti-Tumor Effects of Liposomal Antisense Oligonucleotides in Neuroblastoma  
Brignole C, Pastorino F, Pagnan G, Marimpietri D, Cosimo E and Ponzoni M.  
G. Gaslini Children's Hospital, Genoa, Italy
  
- PT-65      Evidence for Immunogenicity of NY-ESO-1 Antigen in Neuroblastoma Patients  
Rodolfo M, Stockert E, Chen Y, Old LJ, Collini P, Luksch R, Fossati-Bellani F, Ranzani T, Dalerba P, Lombardo C, Rivoltini L, Parmiani G and Castelli C.  
Istituto Nazionale per lo Studio e La Cura dei Tumori, Milan, Italy; Ludwig Institute for Cancer Research, MSKCC, NY, USA
  
- PT-66      rAAV-Mediated Long-term Liver-Generated Expression of an Angiogenesis Inhibitor Improves Survival in Mice with Metastatic Neuroblastoma  
Davidoff AM, Nathwani AC, Spurbeck WW, Ng CYC, Zhou J, and Vanin EF.  
St Jude Children's Research Hospital, Memphis, TN, USA
  
- PT-67      Increased Expression of Angiogenic Inhibitors is Associated with Neuroblastoma Differentiation  
Katzenstein HM, Liu S, Crawford SE, Weinstein J, and Cohn SL.  
Northwestern University, Chicago, IL, USA
  
- PT-68      Angiogenesis Inhibition Is an Effective Adjuvant Therapeutic Strategy in Neuroblastoma (NB) Preclinical Models  
Shusterman S, Morowitz MJ, Grupp SA, Barr R, Pawel B, Zhao H, Wang Q, Weiss WA and Maris JM.  
Children's Hospital of Philadelphia and the University of Pennsylvania, USA
  
- PT-69      Lack of Efficacy of Angiostatin in a Human Neuroblastoma Xenograft Model  
Joseph JM, Bouquet C, Opolon P, Morizet J, Aubert G, Rössler J, Gross N, Perricaudet M, Vassal G.  
Institut Gustave Roussy, Villejuif, France; Universitätsklinikum Essen, Germany; CHU Vaudois, Lausanne, Switzerland
  
- PT-70      Development of a Relevant Orthotopic Model of Neuroblastoma for the Evaluation of Antiangiogenic Therapies  
Joseph JM, Opolon P, Morizet J, Bennaceur AL, Aubert G, Dugray A, Lassau N, Gross N, Vassal G.  
Institut Gustave Roussy, Villejuif, France; CHU Vaudois, Lausanne, Switzerland

(last updated  
05-07-02)

## PLENARY SESSION 3 : BIOLOGY AND TRANSLATIONAL

- 8.00 a.m. CHAIRPERSONS: J MARIS and P. AMBROS  
Room "Grands Lacs-Baikal-Victoria"
- 8.15 a.m. TRAIL Pathway-Associated Gene Clusters on 2q33 and 8p21 are Often Methylated in Neuroblastoma  
OB-15 Van Noesel MM, van Bezouw S, Voûte PA, Herman JG, Pieters R, Versteeg R.  
Academic Medical Center, Amsterdam, The Netherlands. The Johns Hopkins Oncology Center, Baltimore, USA and Sophia Children's Hospital, Rotterdam, The Netherlands
- 8.35 a.m. A Novel Mechanism for Potentiation of TRAIL-Induced Apoptosis: Resveratrol Sensitizes Neuroblastoma Cells for TRAIL through p21-Mediated G1 Arrest  
OB-16 Fulda S, Debatin KM.  
University Children's Hospital, Ulm, Germany
- OB-17 Epigenetic Silencing of Caspase-8: a Novel Resistance Mechanism of Neuroblastoma which is Reversed by Demethylating Agents, Histone Deacetylase Inhibitors, IFN $\gamma$  or Caspase-8 Gene Transfer  
Fulda S, Debatin KM.  
University Children's Hospital, Ulm, Germany
- 9.05 a.m. Structural Analysis of Regions Responsible for the Distinct Functions of TrkA and TrkB in Neuroblastoma (NB)  
OB-18 Hishiki T, Minturn JE, Ho R, Ikegaki N, Brodeur GM.  
The Children's Hospital of Philadelphia, PA USA
- 9.25 a.m. p73 $\alpha$  over Expression in SH-SY5Y Neuroblasts Induced Nuclear Accumulation of Endogeneous p53 Protein  
OB-19 Goldschneider D, Blanc E, Raguéñez G, Legrand A, Taisant O, Le Roux G, Bénard J, Haddada H, Douc-Rasy S.  
Institut Gustave Roussy, Villejuif, France
- 9.45 a.m. NGF Regulates N-myc Levels Via MAP Kinase Pathway in Neuroblastoma  
OB-20 Woo CW, Wada RK, Thiele CJ.  
National Cancer Institute, NIH and Cancer Research Center of Hawaii and the Kapiolani Health Research Institute, USA
- 10.05 a.m. The Role of the MEIS Homeobox Genes in Neuroblastoma Tumorigenesis  
OB-21 Geerts D, Schilderink N, Jorritsma G, and Versteeg R.  
Academic Medical Centre, Amsterdam, The Netherlands
- 10.30 a.m. Break  
Coffee & Viennoiserie

[Home](#)[Join us](#)[Location](#)[Agenda](#)[Registration](#)[Abstract submission](#)

(last updated  
05-07-02)

## PLENARY SESSION 4 : BIOLOGY AND TRANSLATIONAL

- 11.00 a.m. CHAIRPERSONS: NK CHEUNG and GP TONINI  
Room "Grands Lacs-Baïkal-Victoria"
  
- 11.00 a.m. PTEN-AKT-MDM2-p53 Axis in Neuroblastoma Therapeutics  
OTR-01 Dey N, Su J.D, Erdreich-Epstein A, Reynolds C.P, Moritake H, Sugimoto T,  
Durden D.L.  
Indiana University School of Medicine, Herman B Wells Center for Pediatric  
Research, Indianapolis, IN Childrens Hospital Los Angeles, Los Angeles, CA,  
USA and Miyazaki Medical College, Miyazaki, Japan
  
- 11.20 a.m. Identification of Angiogenesis Inhibitors Upregulated in TrkA Transfected  
SY5Y Neuroblastoma Cells by Gene Expression Profiling with  
Oligonucleotide Arrays  
OTR-02 Schramm A, Schulte JH, Klein-Hitpass L, Klenk M, Brodeur GM,  
Schweigerer L, Havers W, Eggert A.  
University Children's Hospital of Essen, Germany and The Children's Hospital  
of Philadelphia, PA, USA
  
- 11.40 a.m. Favorable Neuroblastoma Genes and Molecular Therapeutics of  
Neuroblastoma  
OTR-03 Tang X, Kim D, Robinson M, Titus T, and Ikegaki N.  
The Children's Hospital of Philadelphia, PA USA
  
- 12.00 a.m. Biological Parameters of Disseminated Tumor Cells give Important  
Information on the Response to Cytotoxic Treatment and Outcome of Stage 4  
Patients  
OTR-04 Mehes G, Luegmayr A, Ambros IM, Ladenstein R, Gadner H, Ambros PF.  
CCRI, St. Anna Kinderspital, Vienna, Austria
  
- 12.30 p.m. Lunch  
Room "Les Parcs"

[Home](#)[Join us](#)[Location](#)[Agenda](#)[Registration](#)[Abstract  
submission](#)

## PARALLEL SESSION 3 : TRANSLATIONAL

- 2.00 p.m. CHAIRPERSONS: M. HABER and D. VALTEAU-COUANET  
Room "Grands Lacs-Baikal-Victoria"
- 2.00 p.m. Gene Expression Profiles as a Prognostic Tool for Neuroblastoma  
OTR-05 Berwanger B, Bergmann E, Hartmann O, Nielsen D, Kartal A, Gebhard S,  
Ultsch A, Krause M, Christiansen H and Eilers M.  
Institute of Molecular Biology and Tumour Research; University Children's  
Hospital ; Institute for Informatics ; Marburg, Germany
- 2.15 p.m. The MYCN Oncogene as a Target for Cancer Therapy: Reporter Gene Assay  
Identification of MYCN Transcriptional Activity Inhibitors  
OTR-06 Lu X., Pearson ADJ., Lunec J.  
University of Newcastle upon Tyne, Newcastle upon Tyne, UK
- 2.30 p.m. Retinoid-Regulated Transcriptional Target Genes in Neuroblastoma Cells  
OTR-07 Smith S, Cheung B, Yan J, Norris M, Haber M and Marshall G.  
Children's Cancer Institute Australia for Medical Research, Sydney,  
Australia
- 2. 45 p.m. C75 is an Effective Inducer of Apoptosis in Human Neuroblastoma Cells  
OTR-08 Fentz AK, David KA.  
University of Hamburg, Germany
- 3.00 p.m. Identification of a Novel Gene, Nbla0219/BMCC1, with the BNIP2 and  
Cdc42GAP Homology (BCH) Domain: Possible Pro-Apoptotic Function and  
Association between High Expression of BMCC1 and Favorable Prognosis  
in Neuroblastomas  
OTR-09 Machida T, Ohira M, Kanamori T, Fukumura M, Hamano S, Morohashi A,  
Mihara M, Hirato J, Akazawa C, Kohsaka S, Adachi W, Amano J, and  
Nakagawara A.  
Chiba Cancer Center Research Institute, Chiba ; Shinshu University School  
of Medicine., Matumoto ; Gunma University School of Medicine, Gunma ;  
National Institute of Neuroscience, Tokyo; Japan
- 3.15 p.m. Induction of Caspase 8 by IFN- $\gamma$  Renders some NB Cells TRAIL Sensitive  
but Reveals a Lack of Membrane TR1/TR2 also Contributes to TRAIL  
Resistance in NB  
OTR-10 Yang X, Merchant M, Kontny U, Mackall C, Thiele CJ.  
NCI, Bethesda, MD; Children's Hospital, Albert-Ludwigs-University,  
Freiburg, Germany
- 3.30 p.m. Break  
Coffee & vienoeseries
- 4.00 p.m. CHAIRPERSONS: T. PHILIP and A. EVANS  
Role of Host-Derived and Tumor Cell-Derived MMPs in Neuroblastoma  
Progression  
OTR-11 Chantrain C, Shimada H, Coussens L, Shalinsky D, DeClerck YA.  
Children's Hospital Los Angeles, University of Southern California ;  
University of California San Francisco ; Pfizer/Agouron Pharmaceuticals,  
Inc. La Jolla ; CA, USA
- 4.15 p.m. Resistance to Chemotherapy is Mediated by TrkB in Neuroblastomas (NBs)  
OTR-12 Ho R, Hishiki T, Minturn JE, Ikegaki N, Evans AE, Brodeur GM.  
The Children's Hospital of Philadelphia, PA, USA
- 4.30 p.m. New Prognostic Markers in Locoregional and 4S  
Neuroblastoma:Chromosomal alterations in 3(p) and 11(q)

[Home](#)[Join us](#)[Location](#)[Agenda](#)[Registration](#)[Abstract  
submission](#)

## Agenda

- OTR-13 Spitz R, Hero B, Ernestus K, Berthold F.  
Children's Hospital, Cologne, Germany
- 4.45 p.m. Dendritic Cells (DC) for NK/LAK Activation : Rationale for Multicellular  
Immunotherapy in Neuroblastoma (NB)
- OTR-14 Valteau-Couanet D, Maincent K, Leboulleire C, Tournier M, Hartmann O,  
Beaujean F, Boccaccio C, Zitvogel F, and Angevin E.  
Institut Gustave Roussy, Villejuif, France
- 5.00 p.m. Human Anti-Idiotypic Antibodies against Anti-GD2-Antibody ch 14.18  
Cloned by Phage Display as a Possible Tumor Vaccine against  
Neuroblastoma
- OTR-15 Uttenreuther-Fischer MM, Krueger J, Fischer P.  
Charite Children's Hospital, Humboldt University, Berlin, Germany

## PARALLEL SESSION 4: CLINICAL

- 2.00 p.m. CHAIRPERSONS: F. BERTHOLD and JM. ZUCKER  
Room "Michigan"
- 2.00 p.m. MYCN Copy Number and Hyperdiploidy: Do They Define a Favourable Prognostic Group in Neuroblastoma Patients between 12 and 24 Months of Age? A COG Study  
OC-01 George R, London WB, Maris JM, Cohn SL, Diller L, Look AT.  
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;  
Children's Oncology Group, University of Florida, Gainesville, FL; The Children's Hospital of Philadelphia, Philadelphia, PA; Northwestern University, Chicago, IL ; USA
- 2.15 p.m. Prognostic Relevance of CD44 and trkA Expression in Localized Neuroblastoma  
OC-02 Ernestus K, Hero B, Spitz R, Christiansen H, Schwab M, Berthold M.  
University of Cologne, Marburg, DKFZ Heidelberg, Germany
- 2.30 p.m. A Population Based Controlled Trial of Neuroblastoma Screening at One Year of Age in Germany  
OC-03 Schilling FH, Spix C, Berthold F, Erttmann R, Fehse N., Hero B, Klein G, Sander J, Schwarz K, Treuner J, Zorn U, Michaelis J.  
Stuttgart, Mainz , Cologne, Hamburg, Hannover ; Germany
- 2. 45 p.m. Dumbbell Localised Neuroblastoma  
OC-04 Plantaz D, Michon J, Coze C, Valteau-Couanet D, Perel Y, Leverger G, Bergeron C, Thomas C, Chastagner P, Munzer C, Rubie H  
On the behalf of the French Society of Paediatric Oncology, France
- 3.00 p.m. Incidence and Time Frame of Regression in Stage 2 and Stage 3 Neuroblastoma  
OC-05 Hero B, Simon T, Benz-Bohm G, Scheel-Walter HG, Schilling FH, Berthold F  
Universities of Cologne, Tübingen, Stuttgart, Germany
- 3.15 p.m. Impact of Radiotherapy for High Risk Neuroblastoma: a Children's Cancer Group Study  
OC-06 Haas- Kogan D, Swift P, Selch M, Haase G, Seeger R, Gerbing R, Stram D, Matthay K.  
University California San Francisco, CA; for the Children's Oncology Group, Arcadia, CA, USA
- 3.30 p.m. Break  
Coffee & vienoeseries
- CHAIRPERSONS: B DE BERNARDI and H. RUBIE
- 4.00 p.m. Neoplastic Contamination of Leukaphereses in Neuroblastoma is Associated with Poor Bone Marrow Response  
OC-07 Faulkner LB, Garaventa A, Marchi C, Tintori V, Lacitignola L, Bambi F, Bernini G and De Bernardi B.Meyer  
Children's Hospital, Firenze, and Gaslini Children's Hospital, Genova; Italy
- 4.15 p.m. Rationally Designed Hydrolytically Activated Etoposide Prodrugs, a Novel Strategy for the Treatment of Neuroblastoma  
OC-08 Lode HN, Lange B, Schroeder U, Huebener N, Jikai J, Wenkel J, Wrasidlo W, Gaedicke G.  
Charité Children's Hospital, Berlin, Germany

[Home](#)[Join us](#)[Location](#)[Agenda](#)[Registration](#)[Abstract submission](#)

- 4.30 p.m. <sup>131</sup>I-MIBG with Myeloablative Chemotherapy and Autologous Stem Cell Transplant (ASCT) in Refractory Neuroblastoma; a New Approaches to Neuroblastoma Therapy (NANT) Study  
OC-09 Matthay K, Yanik G, Huberty J, Hawkins R, Hasegawa B, Veatch J, Hasenauer B, Price D, Villablanca J, Charron M, Brophy P, Sisson J, Reynolds CP, Groshen S, Seeger R, Maris J.  
UCSF, San Francisco, CA; University of Michigan, Ann Arbor, MI; University of Philadelphia, PA; Children's Hospital Los Angeles, and USC, Los Angeles, CA, USA
  
- 4.45 p.m. Cellular Immunotherapy for Neuroblastoma Utilizing CD8+ CTL Clones Genetically Engineered to Express the CE7R Chimeric Immunoreceptor  
OC-10 Park J, Cooper L, Slovak M, and Jensen M.  
Children's Hospital and Regional Medical Center, Fred Hutchinson Cancer Research Center, Seattle WA; City of Hope National Medical Center, Duarte, CA, US
  
- 5.00 p.m. 13-cis-Retinoic Acid Improves Overall Survival Following Myeloablative Therapy for High-Risk Neuroblastoma: a Randomized Children's Cancer Group (CCG) Study  
OC-11 Reynolds CP, Villablanca JG, Gerbing RB, Stram DO, Seeger RC, and Matthay KK.  
Children's Hospital Los Angeles for the Children's Cancer Group, Arcadia, USA

## POSTER SESSION 3 : GENETICS

CHAIRPERSONS: S. COHN and J.BENARD  
Room "Léman"

- PG-01 A Region on Chromosome 19 Modifies Tumor Susceptibility in a Mouse Model for Neuroblastoma  
Hackett C, Mao JH, Ballmain A, DeYoung J, and Weiss WA.  
University of California, San Francisco, CA, USA
- PG-02 Karyotypic Evolution in Neuroblastoma  
Betts DR, Cohen N, Leibundgut KE, Kühne T, Caflisch U, Greiner J, Traktenbrot L, Riesch M, Niggli FK.  
University Children's Hospital, Zürich, Bern, Basel, Children's Hospital, Luzern, St. Gallen, Switzerland, The Chaim Sheba Medical Center, Israel
- PG-03 Combined 24-color Karyotyping and CGH Analysis Indicates a Predominant Instability of Early Replicating Chromosome Regions in Neuroblastoma  
Schleiermacher G, Janoueix-Lerosey I, Combaret V, Derré J, Aurias A and Delattre O.  
Institut Curie, Paris and Centre Léon Bérard, Lyon, France
- PG-04 Neuroblastoma CGH Data Revisited : Identification of Genetic Subgroups by Cluster Analysis  
Vandesompele J, Baudis M, De Preter K, Van Roy N, Laureys G, Speleman F  
Ghent University Hospital, Belgium and Stanford University Medical Center, Stanford, USA
- PG-05 Comparative Geomic Hybridation (CGH) Analysis Identifies New Chromosomal Gains/Losses in Neuroblastoma  
Defferrari R, Mazzocco K, Coco S and Tonini GP.  
Advanced Biotechnology Center, National Institute for Cancer Research, Genoa, Italy
- PG-06 Novel Regions of Allelic Imbalance Identified by Genome-Wide Analysis of Neuroblastoma  
Mora J, Cheung NKV, Oplanich S, Chen L, Gerald WL.  
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
- PG-07 Analysis of CHD5, a New Member of the Chromodomain Family and Candidate 1p36.3 Suppressor Gene in Neuroblastomas  
Thompson PM, Gotoh T, White PS, Brodeur GM.  
The Children's Hospital of Philadelphia, PA, USA
- PG-08 Analyses of Genes in the Neuroblastoma Deletion Region in 1p36; Rare Mutations or Variations in DFFA and UBE4B Genes in Neuroblastoma Tumors  
Krona C, Ejeskär K, Abel F, Sjöberg RM, Bjelke J, Björk E and Martinsson T.  
Sahlgrenska University Hospital-East, Göteborg, Sweden, and Murdoch Children's Research Institute, Melbourne, Australia
- PG-09 Gene Expression Profiling of the 1p36 Region in Neuroblastoma Using cDNA Microarrays  
Janoueix-Lerosey I, Monteiro M, Gruel N, Loriod B, Nguyen C, Novikov E and Delattre O.  
Institut Curie, Paris, and Centre d'Immunologie de Marseille-Luminy, Marseille, France
- PG-10 Characterization of Genes Located within a 1 Mbp Smallest Region of Overlapping Deletion in 1p36 in Human Neuroblastoma

[Home](#)[Join us](#)[Location](#)[Agenda](#)[Registration](#)[Abstract  
submission](#)



Henrich K, Bauer A, Westermann F, Savelyeva L, Claas A, Praml C, Berthold F and Schwab M.  
Deutsches Krebsforschungszentrum, Heidelberg, Germany

- PG-11 Positional Cloning of Translocation Breakpoints of a Constitutional 1;17 Translocation in a Neuroblastoma Patient  
Van Roy N, Vandesompele J, Staes K, Laureys G, Van Gele M, De Smet E, Vandepoele K, Berx G, Van Roy F, Speleman F.  
Ghent University Hospital and VIB-Ghent University, Ghent, Belgium
- PG-12 Breakpoint Position on 17q Identifies the Most Aggressive Neuroblastoma Tumours  
Lastowska M, Cotterill S, Bown N, Cullinane C, Variend S, Lunec J, Strachan T, Pearson ADJ, Jackson MS.  
On behalf of the United Kingdom Children's Cancer Study Group
- PG-13 Establishment of Immortalized Cell Lines from non-MYCN Amplified Neuroblastomas with t(11;17) Translocations  
McConville C, Genus T, Chughtai S, McMullan DJ and Dyer S.  
University of Birmingham and Birmingham Children's Hospital, and Birmingham Womens Hospital, Birmingham, UK
- PG-14 Identification of Genes Associated with MYCN overexpression in Neuroblastoma Using Microarray-Based Gene Expression Analysis  
Alaminos M, Mora J, Cheung NKV, Qin J, Smith A, Gerald W.  
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
- PG-15 Array CGH Analysis of DNA Copy Number in Primary Neuroblastomas and Cell Lines  
Tomioka N, Ohira M, Misra A, Albertson D, Pinkel D, Feuerstein B, Nakagawara A.  
Chiba Cancer Center Research Institute, Chiba, Japan, and UCSF Cancer Center, San Francisco, USA
- PG-16 Very High Levels of Micro-Foci inducing Virus (MFV) Sequences in Neuroblastomas with MYCN Amplification  
Rovigatti U, Keller R, Bachi T, Speleman F and Tam A.  
University of Pisa Medical School, Pisa, Italy; Universitatsspital, Zurich, Switzerland, Ghent University Hospital, Ghent, Belgium, and Genelabs, Redwood City, CA, USA
- PG-17 Application of Microarray Technology for Evaluation of Gene Copy Number and Gene Expression Profile in Neuroblastoma  
Scaruffi P, Parodi S, Sulman EP, Rappaport E, Maris JM, Bonassi S, Fortina P, Tonini GP.  
National Institute for Cancer Research , Genoa, Italy; The Children's Hospital of Philadelphia, Philadelphia, USA
- PG-18 Expression of a Novel Gene Identified in Neuroblastoma Cell Line IMR5 Appears to Depend on its Genomic Coamplification with MYCN  
Fischer M, Skowron M, Mehler K, Berthold F  
University of Cologne, Germany
- PG-19 Co-Amplification of ATBF1 and MYC in Neuroblastoma Cell Line SJNB-12  
Vandesompele J, De Preter K, De Smet E, Laureys G, De Paepe A , Speleman F, I, Van Roy N.  
Ghent University Hospital, Ghent, Belgium
- PG-20 Molecular Pathology of Non-MYCN Amplified, Advanced Stage Neuroblastoma  
Chughtai S, Genus T, Ramani P, Oude Luttikhuis M and McConville C  
On behalf of the UK Children's Cancer Study Group  
University of Birmingham & Birmingham Children's Hospital, UK

- PG-21 NEDL1/Nbla0078 Identified from the Neuroblastoma cDNA Library Is A Novel E3 Ubiquitin Ligase with the HECT-domain and its Expression is Significantly Associated with Favorable Outcome in Primary Neuroblastomas  
Miyazaki K, Okamoto Y, Ozaki Y, Sakamoto M, Kato C, Nimura Y, Hirato J and Nakagawara A.  
Chiba Cancer Center Research Institute, Chiba, Nagoya University School of Medicine, Nagoya and Gunma University School of Medicine, Maebashi, Japan
  
- PG-22 Deletion Mapping at 4p16 Defines a Minimal Deleted Region of 3.0 cM in Human Neuroblastoma  
Perri P, Longo L, Cusano R, Devoto M, Conte M, Seri M, Tonini GP.  
Advanced Biotechnology Center; National Institute for Cancer Research; University of Genoa; Gaslini Children's Hospital - Genoa, Italy
  
- PG-23 Comprehensive Analysis of the 9p21 Region in Neuroblastoma  
Mora J, Alaminos M, Illei P, Cheung NKV, Gerald WL.  
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
  
- PG-24 Microarray Analysis of Telomerase-Positive versus Telomerase-Negative Neuroblastoma Cell Lines  
Schaefer K-L, Braun Y, Wai DH, Baer C, Reynolds CP, Boecker W, Dockhorn-Dworniczak B, Selle B, and Poremba C.  
Gerhard-Domagk-Institute of Pathology, University of Muenster, Muenster; University Children's Hospital of Heidelberg, Heidelberg,; Institute of Pathology, Kempten; Germany, and Children's Hospital Los Angeles, Los Angeles, USA
  
- PG-25 Rearrangements and Increased Expression of Cyclin D1 in Neuroblastoma  
Molenaar J, van Sluis P, Versteeg R and Caron H.  
Academic Medical Centre, University of Amsterdam, Netherlands
  
- PG-26 Identification of Three Novel Amplified and Overexpressed Transcripts in Neuroblastoma  
Vandesompele J, De Preter K, Van Roy N, De Paepe A, Speleman F.  
Ghent University Hospital, Belgium
  
- PG-27 Identification of Novel Human Neuronal Leucine-Rich Repeat (hNLRR) Family Genes and Reciprocal Association of Expression of Nbla10449/hNLRR-1 and Nbla10677/hNLRR-3 with the Prognosis of Neuroblastoma  
Hamano S, Ohira S, Fukumura M, Tsunobuchi H, Isogai E, Nakada K and Nakagawara A.  
Chiba Cancer Center Research, Chiba and St Marianna University School of Medicine, Kawasaki, Japan
  
- PG-28 Identification of Novel Coding Exons within the Neuroblastoma Amplified Gene NAG  
Scott DK, Pearson ADJ, Lunec J.  
Cancer Research Unit, University of Newcastle upon Tyne; Royal Victoria Infirmary, Newcastle upon Tyne, UK
  
- PG-29 Mutation and Expression Analysis of the von Hippel-Lindau Gene in Neuroblastoma  
Hoebeek J, Vandesompele J, Van Roy N, De Smet E, Laureys G, De Paepe A and Speleman F.  
Ghent University Hospital, Belgium

## POSTER SESSION 4 : CLINICAL

CHAIRPERSONS: R. LADENSTEIN - T. SUGIMOTO  
Room "Lugano-Constance"

- PC-01 Comparative Genomic Hybridization (CGH) Analysis of Neuroblastoma Associated with Lung, Brain, or Meningeal Metastases  
Couturier J, Legrand-Huon I, Bénard J, Delattre O, Seeger R, Michon J, Valteau-Couanet D, Matthay K.  
Institut Curie, Paris; Institut Gustave-Roussy, Villejuif, France; USC and Childrens Hospital Los Angeles, Los Angeles ; UCSF, San Francisco, CA, USA
- PC-02 DNA Index and S Phase as Potential Tools for Profiling Localized and Stage 4S Neuroblastomas  
Chassevent A, Bénard J, Valteau-Couanet D, Valo I, Henry C, Joyaux D, Cantais S, Barrois M, Michon J, Rubie H, Hartmann O.  
Centre Paul Papin, Angers ; Institut Gustave Roussy, Villejuif ; Société d'Oncologie Pédiatrique Française, France
- PC-03 Comprehensive Analysis of Tumoral DNA Content Reveals Clonal Ploidy Hetero-Geneity: Clinical and Prognostic Significance in Neuroblastoma  
Mora J, Alaminos M, Cheung NKV, Juan G, Illei P, Gerald WL.  
Memorial Sloan-Kettering Cancer Center, New York, USA
- PC-04 A New Splicing Variant of Tyrosine Hydroxylase: Implications for the Detection of Minimal Residual Disease in Neuroblastoma  
Gallego S, Parareda A, Villaescusa JC, Sanchez de Toledo J.  
Hospital Universitari Vall d'Hebron. Barcelona, Spain
- PC-05 Expression of DNp73 is a Molecular Marker for Adverse Outcome in Neuroblastoma Patients  
Casciano I, Pagnan G, Banelli B, Croce M, Raffaghello L, Mazzocco K , Boni L, Allemanni G, Ferrini S, Tonini GP, Ponzoni M and Romani M.  
Istituto Nazionale per la Ricerca sul Cancro , Istituto G. Gaslini, CBA , Genova, Italy
- PC-06 Quantitation of GD2 Synthase mRNA by Real-Time Reverse Transcription-PCR: Clinical utility in Evaluating Adjuvant Therapy in Neuroblastoma  
Cheung IY, LoPiccolo MS, Kushner BH, Kramer K, Cheung KV.  
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
- PC-07 Improved Real-Time Quantitative PCR Assay Allows Detection of MYCN Amplification in Small Subsets of Neuroblastoma Cells  
De Preter K, Vandesompele J, Combaret V, Lunec J, Laureys G, Van Roy N, and Speleman F.  
Ghent University Hospital, Belgium, Centre Léon Bérard, Lyon, France, University of Newcastle, Newcastle upon Tyne, UK
- PC-08 P16 Expression is Associated with Advanced Stage Neuroblastoma and not Correlated with Expression of Id2: A Children's Oncology Group Study  
Gebauer S, Diccianni MB, Omura-Minamisawa M, Cohn SL, Seeger R and Yu AL.  
University of California, San Diego, Northwestern University, Chicago, Children's Hospital, Los Angeles, USA
- PC-09 Imaging with Tc-99m-Sestamibi Does not Predict Drug Resistance or Outcome in Childhood Neuroblastoma

[Home](#)[Join us](#)[Location](#)[Agenda](#)[Registration](#)[Abstract  
submission](#)

De Moerloose B, VandeWiele C, Dhooge C, Swerts K, Benoit Y, Philippé J and Laureys G.  
Ghent University Hospital, Ghent, Belgium

- PC-10      Detection of tumour cells in bone marrow and peripheral blood from neuroblastoma patient. a comparative study of morphological, histological, immunocytological and molecular analyses  
Corrias MV, Faulkner LB, Rosanda C , Callea F, Lo Piccolo MS , Boni L, Gambini C, Marchi C, Scaruffi P, Occhino M, Lacitignola L, Tonini GP, Lualdi S, Pistoia V, De Bernardi B, and Garaventa A.  
Gaslini Children's Hospital and National Institute for Cancer Research, Genova; Meyer Children's Hospital, Firenze; and Civic Hospital, Brescia; Italy
  
- PC-11      Micrometastatic Disease Response Assessment in Neuroblastoma  
Negri F, Sementa AR, Garaventa A, Marchi C, Lacitignola L, De Bernardi B, and Faulkner LB.  
Giannina Gaslini Children's Hospital, Genova, and Meyer Children's Hospital, Firenze; Italy
  
- PC-12      Quantitative Analysis of Tyrosine Hydroxylase mRNA in Blood and Bone Marrow Follows the Clinical Course of Neuroblastoma  
Träger C, Kogner P, Kullman A, Kågedal B.  
Linköping University and Childhood Cancer Research Unit, Karolinska Institute, Sweden
  
- PC-13      Clinical Significance of Minimal Residual Disease in Bone Marrow, Blood and Leukapheresis Detected by RT-PCR for the Tyrosine Hydroxylase in Stage 4 Neuroblastoma : a French Pilot Study  
Bennaceur-Griscelli A, Valteau-Couanet D, Michon J, Aupérin A, Bayle C, Vielh P, Leclercq E, Courtier MH, Beaussier PS, Hartmann O.  
Institut Gustave Roussy, Villejuif, ; Institut Curie, Paris, France
  
- PC-14      Bone Marrow Anti-GD2 Immunocytology Identifies a Substantial Proportion of Chemotherapy-Resistant Patients  
Faulkner LB, Garaventa A\*, Marchi C, Tintori V, Lacitignola L, Bernini G, and De Bernardi B, on behalf of the Italian Cooperative Group for Neuroblastoma.  
Meyer Children's Hospital, Firenze, and Gaslini Children's Hospital, Genova; Italy
  
- PC-15      TH, Gage and Mage as MRD Markers in Neuroblastoma  
Fernández JM, Oltra S, Cañete A, Orellana C, Martínez-Castellano F, Castel V.  
Hospital "La Fe", Valencia, Spain
  
- PC-16      Bone Marrow (BM) Cytogenetic Abnormalities in Patients with High-Risk Neuroblastoma (NB)  
Kramer K, Kushner BH, Jhanwar SC, Cheung NKV.  
Memorial Sloan-Kettering Cancer Center, NY, USA
  
- PC-17      Evolving Significance of Prognostic Markers Associated with Treatment Improvement Stage 4 Neuroblastoma  
Mora J, Gerald WL, Qin J, and Cheung NKV.  
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
  
- PC-18      Efficacy and Safety of Ex Vivo Bone Marrow (BM) Purging of Neuroblastoma (NB) Using Anti-GD2 Antibody 3F8  
Cheung I, LoPiccolo S, Collins N, Kushner B, Cheung NK.  
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
  
- PC-19      Immunomagnetic Purging of Neuroblastoma from Peripheral Blood Stem Cells Concentrated by Carbonyl Iron Magnetic Fractionation  
Tang YM, Billups C, Seeger RC, Villablanca JG, Reynolds CP.  
Childrens Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, CA; Childrens Oncology Group, USA

- PC-20 Purging Neuroblastoma Cells from Bone Marrow or Peripheral Blood Using a VDEPT Method with Rabbit Carboxylesterase and CPT-11: Application to Specimens with >1% Tumor Burden  
Wagner LM, Potter PM, Danks MK.  
St. Jude Children's Research Hospital, Memphis, TN. USA
  
- PC-21 Phase I Trial of Oral [N-(4-hydroxyphenyl) retinamide] (4-HPR) in Children with Resistant/Recurrent Solid Tumors: A Children's Cancer Group Study (CCG 09709)  
Villablanca JG, Ames MM, Reid JM, Bagniewski P, Krailo M, Reynolds CP.  
University of Southern California, Los Angeles, CA; Mayo Clinic, Rochester, Minnesota; Children's Cancer Group, Arcadia, CA, USA
  
- PC-22 Phase I Trial of Fenretinide in Children with Neuroblastoma  
Garaventa A, Formelli F, Luksch R, Lo Piccolo MS, Montaldo PG, Pizzitola MR, Boni L, Ponzoni M, De Censi A, Cavadini E, De Bernardi B, Fossati Bellani F.  
Gaslini Children's Hospital, Genova; National Cancer Institute, and European Institute of Oncology, Milano, Italy
  
- PC-23 Pilot Study of Buthionine Sulfoximine (BSO) Combined with Non-Myeloablative Melphalan (L-PAM) in Refractory Neuroblastoma  
Anderson CP, Seeger RC, Bailey HH, Reynolds CP.  
Childrens Hospital of Los Angeles and University of Southern California, Los Angeles, CA; University of Wisconsin, Madison WI, USA
  
- PC-24 Lymphotoxin (Lptn) and IL-2 Gene-Modified Allogenic Tumor Vaccine in Patients with Advanced Neuroblastoma  
Rousseau RF, Haight AE, Hirschmann-Jax C, Rill DR, Zhuyong M, Smith SC, Inman S, Cooper K, Alcoser P, Popeck E, Davidoff A, Bowman LC, Brenner MK, Strother D.  
Baylor College of Medicine, Houston, TX ; St. Jude Children's Research Hospital, Memphis, TN, USA
  
- PC-25 Oral Topotecan Therapy for Relapsed or Refractory Neuroblastoma (NB)  
Kramer K, Kushner BH, Cheung NKV.  
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
  
- PC-26 A Phase-II-Study with Topotecan and Etoposide in Relapsed Neuroblastoma  
Längler A, Hero B, Berthold F.  
Children's hospital, University of Cologne; Germany
  
- PC-27 Irinotecan and High-Dose Cyclophosphamide (HD-CPM) for Neuroblastoma (NB)  
Brian H. Kne, Kushner BH, Kramer K, Cheung NKV.  
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
  
- PC-28 Phase II study of High Dose <sup>131</sup>I-MIBG with Hematopoietic Stem Cell Transplant (HSCT) in Refractory Neuroblastoma  
Matthay K, Maris JM, Weiss B, Huberty J, Price D, Glidden D, Veatch J, Brophy P, Hasegawa B, Charron M, Hawkins R.  
Univ of California San Francisco, CA, , and CHOP/ Univ. Penn., Philadelphia, PA
  
- PC-29 Topotecan plus Myeloablative Thiotepa and Carboplatin for Neuroblastoma (NB)  
Kushner BH, Kernan NA, Kramer K, Reich L, Boulad F, Cheung NKV.  
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
  
- PC-30 Treatment of Metastatic Neuroblastoma (NB) with Anti-GD2 Murine Monoclonal Antibody 3F8: The Hong Kong Experience  
Chan GCF, Shing MMK, Luk CW, Ling SC, Lee ACW  
Hong Kong Paediatric Haematology / Oncology Study Group, Hong Kong

- PC-31 Ch14.18 Anti-GD 2 Antibody Treatment in High Risk Neuroblastoma. Results of 2 Consecutive Phase II Studies  
Ladenstein R, Poetschger U, DeBernardi B , Garaventa A, Handgretinger R, Dagdelen M, Kreyenberg H, Holter W, Gadner H.  
St. Anna Kinderspital, Vienna, Austria , Giannina Gaslini Children's Hospital, Genova , Italy, University Tübingen, Germany
  
- PC-32 Anti-GD2 Antibody 3F8 and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), plus 13-Cis-Retinoic Acid (CRA), for Maintenance of Complete/Very Good Partial Remission (CR/VGPR) of Neuroblastoma (NB)  
Kushner BH, Kramer K, Cheung NKV.  
Memorial Sloan-Kettering Cancer Center, New York, NY
  
- PC-33 Final Report on a Randomized Phase II Study of s.c. IL 2 after MGT/SCR in Stage 4 Neuroblastoma  
Ladenstein R, Michon J, De Bernardi B, Bergeron C, Lewis J, Stein J, Kohler J, Shaw P, Maral J, Poetschger U, Modritz D, Holter W, Gadner H.  
Study center: CCRI/ St. Anna Children's Hospital,Vienna, Austria
  
- PC-34 Treatment Optimization in N8 with the Goal to Eradicate Minimal Residual Disease (MRD) while Preventing CNS Relapse and Treatment-Related Leukemia  
Cheung NKV, Kushner BH, LaQuaglia M, Kramer K, Wolden SL, Kernan NA.  
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
  
- PC-35 Autologous Hematopoietic Stem Cell Transplant (AHSCT) before Disease Progression in Children in Stage IV Neuroblastoma Diagnosed after the First Year of Life  
Butturini A, Villablanca J, , Reynolds P, Hasenauer B, Edelman B, Seeger RC.  
Children's Hospital Los Angeles, USA
  
- PC-36 Myeloablative Therapy with Purged Autologous Hematopoietic Stem Cell Transplant (AHSCT) for Stage 4 Neuroblastoma Diagnosed after One Year of Age in Partial Response (PR) after Induction Therapy  
Butturini A, Villablanca JG, Reynolds CP, Hasenauer B, Edelman B, Seeger RC.  
Children's Hospital Los Angeles and Keck School of Medicine, USC, Los Angeles, CA, USA
  
- PC-37 Rapid Sequence Tandem Transplant For Advanced Neuroblastoma: Update and Patterns of Relapse  
Grupp SA, Bowman LC, von Allmen D, Guzikowski V, Aplenc R, Shamberger R, Marcus KC, and Diller L.  
Children's Hospitals of Philadelphia, Atlanta and Boston; and Dana-Farber Cancer Institute, Boston, USA
  
- PC-38 Intensified Multimodal Therapy Improves Survival in High-Risk Neuroblastoma  
Kogner P, Borgström P, Karpe B, Lundell G, Hassan M, Winiarski J.  
Karolinska Hospital, Huddinge University Hospital, Karolinska Institutet, Stockholm Sweden
  
- PC-39 Epidemiological Aspects in the German Neuroblastoma Screening Project  
Spix C, Klein G, Berthold F, Erttmann R, Hero B, Sander J, Treuner J, Michaelis J Schilling FH.  
Johannes Gutenberg University, German Childhood Cancer Registry, Mainz; University of Cologne, Children's Hospital, Cologne; University of Hamburg, University Hospitals Eppendorf, Hamburg; Landesgesundheitsamt Niedersachsen, Hannover; Klinikum Stuttgart, Olgahospital, Stuttgart; Germany
  
- PC-40 Neuroblastoma (NB) Screening at 12 Months. French Study from 1995 to 1997

Bergeron C, Chauvin F, Combaret V, Thiesse P, Ranchère-Vince D, Mathieu P, Greffe J, Favrot M, Chappuis JP, David L, Frappaz D and Philip T.  
Lyon, France

- PC-41 Neuroblastic Tumors (NT) and Opsoclonus-Myoclonus Syndrome (OMS).  
The Italian Experience in a 16-year Period  
Conte M, Gambini C, De Bernardi B, Provenzi M, Villa G, Ventura F, Pistoia V.  
Children's Hospital, Genova, and Civic Hospital, Bergamo; Italy
  
- PC-42 Neonatal Localized Neuroblastoma  
Michalowski M, Rubie H, Munzer C, Michon J, Perel Y, Bergeron C, Coze C, Thomas C, Valteau-Couanet D, Guitard J, Guys JM, Piolat C, Plantaz D.  
On the behalf of the French Society of Paediatric Oncology, France
  
- PC-43 Disseminated Neuroblastoma in Children Older than 1 Year at Diagnosis.  
Comparable Results with 3 Consecutive High-Dose Protocols of the Italian Cooperative Group for Neuroblastoma (ICGNB)  
De Bernardi B, Casale F, Carli M, Mancini A, Donfrancesco A, Rizzo A, Conte M, Nicolas B, Boni L, Bruzzi P, for the ICGNB
  
- PC-44 Results of Risk Adapted Treatment According to the Austrian Neuroblastoma Trial A-NB94  
Ladenstein R, Poetschger U, Ambros PF, Gadner H  
For the Austrian Cooperative Pediatric Oncology Group (AGPHO)  
St. Anna Kinderspital, Vienna, Austria
  
- PC-45 Treatment Strategy for Neuroblastoma Infants in Japan  
Iehara T , Hamazaki M, Tanaka T, Hosoi H, Sawada T, Sugimoto T.  
On behalf of the Japanese Infantile Neuroblastoma Cooperative Study Group  
The Japanese Infantile Neuroblastoma Cooperative Study Group and Kyoto Prefectural University of Medicine, Kyoto, Japan
  
- PC-46 Neuroblastoma in a Multiracial Asian Population- a Combined Singapore and Malaysian Perspective  
Rajalingam V, Yong MH, Lin HP, Ariffin H, Knight L, Tan AM, Chan MY, Quah TC.  
KK Women`s and Children`s Hospital, National University Hospital, Singapore and University Hospital, Malaysia
  
- PC-47 Increased Incidence of Congenital Cardiovascular Malformations in Patients with Neuroblastoma  
George R, Lipschutz SE, Lipsitz SR, Colan SD, Diller L.  
Harvard Medical School, Boston MA, University of Rochester Medical Center, Rochester, NY, Medical University of South Carolina, Charleston, SC, USA
  
- PC-48 Radiographic Assessment of Resectability of Locoregional Disease in Children with High-Risk Neuroblastoma During Neoadjuvant Chemotherapy  
Davidoff AM, Corey BL, Rao BN, Hoffer FA, Bowman LC, Furman WL, Santana VM and Shochat SJ.  
St. Jude Children's Research Hospital, Memphis, Tennessee, USA
  
- PC-49 The Role of Surgery in Stage 4 Neuroblastoma  
Castel V, Tovar JA , Costa E, Cañete A, Cuadros J, Ruiz-Jimenez JJ.  
On behalf of the Spanish Neuroblastoma Group
  
- PC-50 Localized Cervical Neuroblastoma  
Haddad M, Helardot P, Couanet D, Gauthier F, Neuenschwander S, Faure F, Chappuis JP, Bergeron C, Munzer C, Rubie H, Guys JM.  
On the behalf of the French Society of Pediatric Oncology.  
Hôpital d'Enfants de la Timone, Marseille, France
  
- PC-51 Long Term Results and Risk Profile in Stage 4 Neuroblastoma over 1 Year of Age

Berthold F, Spix C, Kremens B, Simon T, Handgretinger R, Hero B.  
Children's Hospitals, Universities of Cologne, Essen, Mainz, Memphis,  
Germany and USA

- PC-52      Hearing Loss in Long-Term Survivors of Neuroblastoma  
Simon T, Hero B, Dupuis W, Selle B, Berthold F.  
Children's Hospital, Cologne, Karlsruhe, Heidelberg, Germany
  
- PC-53      Neuropsychological and Psychosocial Resiliency in Children Treated for  
Neuroblastoma  
Carpentieri SC, Diller L.  
Dana-Farber Cancer Center, Children's Hospital, Boston, and Harvard Medical  
School, Boston MA, USA
  
- PC-54      Second Tumour after Radiometabolic Therapy for Neuroblastoma. a  
Mono-Institutional Experience  
Garaventa A, Haupt R, Hanau G, Conte M, De Bernardi B, Gambini C, Di  
Cataldo A, Villavecchia GP, Cabria M, Bertolazzi L.  
Gaslini Children's Hospital, Galliera Hospital, Genova; University of Catania;  
Civic Hospital, Alessandria; Italy
  
- PC-55      MLL Translocation in Treatment-Related all Emerged after Marrow Harvest  
and before Radioimmunotherapy during N7 Neuroblastoma Treatment  
Raffini LJ, Cheung NKV, Rappaport EF, Felix CA.  
Children's Hospital of Philadelphia, Philadelphia, PA and Memorial  
Sloan-Kettering Cancer Center, New York, NY, USA



## PLENARY SESSION 5 : TRANSLATIONAL

- 8.00 a.m. CHAIRPERSONS: K. MATTHAY and A. PEARSON  
Room "Grands Lacs-Baikal-Victoria"
- 8.15 a.m. Gene Expression Profiling of Neuroblastoma Clinicobiological Correlation  
OTR-16 Mora J, Cheung NKV, Alaminos M, Qin J, Smith A, Gerald WL Memorial Sloan-Kettering Cancer Center, New York, NY, USA
- 8.30 a.m. GADD153 and Bak, Novel Molecular Targets of Fenretinide-Induced Apoptosis of Neuroblastoma and the Synergistic Response with Chemotherapeutic Drugs  
OTR-17 Lovat P, Oliverio S, Goranov B, Pearson A, Piacentini M and Redfern C. University of Newcastle upon Tyne, UK and University of Tor Vergata, Rome, Italy
- 8.45 a.m. Fenretinide (4-HPR) and 4-HPR + Safingol Prolong Survival in a Xenograft Model of Human Neuroblastoma  
OTR-18 Maurer BJ, Sun BC, Frgala T, Vlckova J, Ernst WA, Gupta S, Vishnuvajjala BR, Reynolds CP.  
Childrens Hospital Los Angeles, University of Southern California, Los Angeles, CA; Molecular Express, Los Angeles CA; National Cancer Institute, Bethesda, MD, USA
- 9.00 a.m. Antitumor Activity of Immunologically-Targeted Liposomal Fenretinide in Human Neuroblastoma  
OTR-19 Raffaghello L, Pagnan G, Pastorino F, Brignole C, Cosimo E, Marimpietri D, Montaldo PG and Ponzoni M.  
G. Gaslini Children's Hospital, Genoa, Italy
- 9.15 a.m. Association of Mutant p53 with Multidrug Resistance in Neuroblastoma Cells  
OTR-20 Norris MD, Xue C, Flemming C, Lock RB, Marshall GM, Haber M.  
Children's Cancer Institute Australia for Medical Research, Sydney Australia
- 9.30 a.m. Increased Incidence of TP53 Mutations in Post-Treatment Neuroblastoma  
OTR-21 Keshelava N, Chen P, Waidyaratne NS, Seeger RC, Triche TJ, Reynolds CP.  
Childrens Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, CA; Childrens Cancer Group, USA
- 9.45 a.m. Inhibition of Angiogenesis in Neuroblastoma by VEGF-Trap  
OTR-22 Kim E, Novikov A, Huang J, Ring L, New T, McCrudden K, Soffer S, Frischer J, Kadenhe A, Middlesworth W, Holash J, Yancopoulos G, Kandel J, Yamashiro D.  
Columbia University, New York, NY and Regeneron Pharmaceuticals, Tarrytown, NY, USA
- 10.00 a.m. Activity of Temozolomide in Relation to DNA Repair in Neuroblastoma  
OTR-23 Vassal G, Terrier-Lacombe MJ, Willington MA, Bénard J, Aubert G, Morizet J, Margison GP.  
Institut Gustave-Roussy, Villejuif, France; Paterson Institute for Cancer Research, Manchester, United-Kingdom
- 10.15 a.m. Break  
Coffee & Viennoiserie

[Home](#)[Join us](#)[Location](#)[Agenda](#)[Registration](#)[Abstract  
submission](#)

(last updated  
05-07-02)

## PLENARY SESSION 6 : CLINICAL

- 10.45 a.m. CHAIRPERSONS: O. HARTMANN and R. SEEGER  
Room "Grands Lacs-Baïkal-Victoria"
- 10.45 a.m. Surgery as Only Treatment for INSS Stage 2 Neuroblastoma without MYCN Amplification: Final Report; an European Prospective Trial  
OC-12 Mosseri V, Michon J, De Bernardi B, Rubie H, Ladenstein R, Castel V, Foot A, Nenadov-Beck M, Laureys G, De Kraker J, Forjaz de Lacerda A, De Rycke Y, Ambros IM, Delattre O, Tonini GP, Gross N, Lunec J, Caron H, Peuchmaur M, D'Amore E, Pearson A and Ambros PF.  
For the LNESG, Institut Curie, Paris, France
- 11.00 a.m. Localized Neuroblastoma and Myc-N Amplification : Improved Survival with High-Dose Chemotherapy and Locoregional Irradiation  
OC-13 Laprie A, Coze C, Valteau-Couanet D, Couturier J, Plantaz D, Schleiermacher G, Bénard J, Chastagner P, Bergeron C, Défachelles AS, Combaret V, Munzer C and Rubie H.  
Hôpital des Enfants, Toulouse, for the SFOP, France
- 11.15 a.m. Prediction of Outcome in Stage 4 Neuroblastoma by MIBG Scintigraphy Score  
OC-14 Matthay K, Edeline V, Tanguy ML, Lumbroso J, Zucker JM, Valteau D, Hartmann O, Michon J.  
University of California, San Francisco, CA, USA; Institut Curie, Paris; Institut Gustave Roussy, Paris, France
- 11.30 a.m. Results of NB 97 SFOP Protocol in Children > 1 Year with a Stage 4 Neuroblastoma  
OC-15 Valteau-Couanet D, Michon J, Perel Y, Bergeron C, Rubie H, Coze C, Rodary C, and Hartmann O.  
For the SFOP Neuroblastoma Group
- 11.45 a.m. A Pilot Trial of a GD-2 Directed Anti-Idiotypic Antibody as a Vaccine for High Risk Neuroblastoma  
OC-16 Yu AL, Batova A, Strother D, Eskenazy A, Castleberry R, Bash R, Matthay K, Diller L.  
University of California in San Diego; Baylor College of Medicine; University. of Maryland in Baltimore; University of Alabama in Birmingham; University of Texas Southwestern Medical School; University. of California San Francisco; Dana Farber Cancer Institute, USA
- 12.00 a.m. Oral  $\beta$ -Glucan Synergizes with Intravenous Monoclonal Antibody 3F8 in the Therapy of Neuroblastoma  
OC-17 Modak S and Cheung NKV.  
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
- 12.15 p.m. G. BRODEUR: CLOSING REMARKS

[Home](#)[Join us](#)[Location](#)[Agenda](#)[Registration](#)[Abstract  
submission](#)